A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients

A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients

Despite the promising therapeutic effects of immune checkpoint blockade (ICB), most patients with solid tumors treated with anti-PD-1/PD-L1 monotherapy do not achieve objective responses, with most tumor regressions being partial rather than complete. It is hypothesized that the absence of pre-exist...

Full description

Bibliographic Details
Main Authors: Michal Bassani-Sternberg, Antonia Digklia, Florian Huber, Dorothea Wagner, Christine Sempoux, Brian J. Stevenson, Anne-Christine Thierry, Justine Michaux, HuiSong Pak, Julien Racle, Caroline Boudousquie, Klara Balint, George Coukos, David Gfeller, Silvia Martin Lluesma, Alexandre Harari, Nicolas Demartines, Lana E. Kandalaft
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-08-01
Series:Frontiers in Immunology
Subjects:
pancreatic adenocarcinoma
dendritic cell vaccine
antigen discovery
neoantigen
cancer immunotherapy
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2019.01832/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2019.01832/full

Similar Items